Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study

Marcel Curlin, Farah Cassis-Ghavami, Amalia S. Magaret, Gregory A. Spies, Ann Duerr, Connie L. Celum, Jorge L. Sanchez, Joseph B. Margolick, Roger Detels, M. Juliana McElrath, Lawrence Corey

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. Methods: We performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. Results: In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. Conclusion: The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalAIDS
Volume25
Issue number2
DOIs
StatePublished - Jan 14 2011
Externally publishedYes

Fingerprint

Adenoviridae
HIV Infections
Case-Control Studies
Immunity
HIV
Neutralizing Antibodies
AIDS Vaccines
Acquired Immunodeficiency Syndrome
Cohort Studies
Serogroup
Confidence Intervals
Human Herpesvirus 2
South America
South Africa
HIV-1

Keywords

  • acquisition risk
  • adenovirus
  • HIV
  • MSM
  • serology
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Curlin, M., Cassis-Ghavami, F., Magaret, A. S., Spies, G. A., Duerr, A., Celum, C. L., ... Corey, L. (2011). Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study. AIDS, 25(2), 153-158. https://doi.org/10.1097/QAD.0b013e328342115c

Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection : A case-control study. / Curlin, Marcel; Cassis-Ghavami, Farah; Magaret, Amalia S.; Spies, Gregory A.; Duerr, Ann; Celum, Connie L.; Sanchez, Jorge L.; Margolick, Joseph B.; Detels, Roger; McElrath, M. Juliana; Corey, Lawrence.

In: AIDS, Vol. 25, No. 2, 14.01.2011, p. 153-158.

Research output: Contribution to journalArticle

Curlin, M, Cassis-Ghavami, F, Magaret, AS, Spies, GA, Duerr, A, Celum, CL, Sanchez, JL, Margolick, JB, Detels, R, McElrath, MJ & Corey, L 2011, 'Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study', AIDS, vol. 25, no. 2, pp. 153-158. https://doi.org/10.1097/QAD.0b013e328342115c
Curlin, Marcel ; Cassis-Ghavami, Farah ; Magaret, Amalia S. ; Spies, Gregory A. ; Duerr, Ann ; Celum, Connie L. ; Sanchez, Jorge L. ; Margolick, Joseph B. ; Detels, Roger ; McElrath, M. Juliana ; Corey, Lawrence. / Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection : A case-control study. In: AIDS. 2011 ; Vol. 25, No. 2. pp. 153-158.
@article{a183a474c78f405591d15797e4ad96bb,
title = "Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: A case-control study",
abstract = "Background: Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. Methods: We performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. Results: In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95{\%} confidence interval 0.8-1.5, P = 0.57) and 1.0 (95{\%} confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. Conclusion: The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.",
keywords = "acquisition risk, adenovirus, HIV, MSM, serology, vaccine",
author = "Marcel Curlin and Farah Cassis-Ghavami and Magaret, {Amalia S.} and Spies, {Gregory A.} and Ann Duerr and Celum, {Connie L.} and Sanchez, {Jorge L.} and Margolick, {Joseph B.} and Roger Detels and McElrath, {M. Juliana} and Lawrence Corey",
year = "2011",
month = "1",
day = "14",
doi = "10.1097/QAD.0b013e328342115c",
language = "English (US)",
volume = "25",
pages = "153--158",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection

T2 - A case-control study

AU - Curlin, Marcel

AU - Cassis-Ghavami, Farah

AU - Magaret, Amalia S.

AU - Spies, Gregory A.

AU - Duerr, Ann

AU - Celum, Connie L.

AU - Sanchez, Jorge L.

AU - Margolick, Joseph B.

AU - Detels, Roger

AU - McElrath, M. Juliana

AU - Corey, Lawrence

PY - 2011/1/14

Y1 - 2011/1/14

N2 - Background: Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. Methods: We performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. Results: In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. Conclusion: The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.

AB - Background: Adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition. Methods: We performed a nested case-control study of Ad5 serostatus among 299 HIV-infected and 590 matched HIV-uninfected persons participating in the Multicenter AIDS Cohort Study (MACS) and in HPTN 039, a study of herpes simplex virus 2 suppression among adults in the United States, South America, and Africa. Appropriate HIV cases and controls were identified in each cohort, and Ad5-neutralizing antibody titers were compared in these two groups. Results: In MACS and HPTN 039, the relative risks of incident HIV infection among Ad5-seropositive vs. Ad5-seronegative individuals were 1.1 (95% confidence interval 0.8-1.5, P = 0.57) and 1.0 (95% confidence interval 0.4-2.3, P = 0.99), respectively. HIV-1 acquisition rates did not vary significantly by Ad5-neutralizing antibody titer. Conclusion: The presence of Ad5-neutralizing antibodies is not linked to the risk of HIV acquisition among populations at elevated risk of HIV infection.

KW - acquisition risk

KW - adenovirus

KW - HIV

KW - MSM

KW - serology

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=78650907071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650907071&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328342115c

DO - 10.1097/QAD.0b013e328342115c

M3 - Article

C2 - 21150554

AN - SCOPUS:78650907071

VL - 25

SP - 153

EP - 158

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -